Dr. Venook Discusses the Approval of Ramucirumab Plus Paclitaxel

Alan P. Venook, MD,
Published: Friday, Nov 07, 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer.

Venook says the approval is a benefit for all oncologists. While ramucirumab was already being combined with other agents, oncologists now know its benefit when combined with paclitaxel.

Ramucirumab’s expanded approval was based on two studies- one evaluating the drug as monotherapy and one evaluating the drug in combination with a taxane, Venook says.

Venook also says that ramucirumab is being evaluated in other disease.

<<< View more from the 2014 Chemotherapy Foundation Symposium

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer.

Venook says the approval is a benefit for all oncologists. While ramucirumab was already being combined with other agents, oncologists now know its benefit when combined with paclitaxel.

Ramucirumab’s expanded approval was based on two studies- one evaluating the drug as monotherapy and one evaluating the drug in combination with a taxane, Venook says.

Venook also says that ramucirumab is being evaluated in other disease.

<<< View more from the 2014 Chemotherapy Foundation Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x